137 related articles for article (PubMed ID: 18231906)
1. Influence of DNA damage and repair upon the risk of treatment related leukemia.
Guillem V; Tormo M
Leuk Lymphoma; 2008 Feb; 49(2):204-17. PubMed ID: 18231906
[TBL] [Abstract][Full Text] [Related]
2. [Therapy-related acute myeloid leukemia: role of DNA repair].
Guièze R; Ravinet A; Hermet E; Maliki Y; de Botton S; Bay JO
Bull Cancer; 2011 Mar; 98(3):247-55. PubMed ID: 21427028
[TBL] [Abstract][Full Text] [Related]
3. Therapy-related leukemia and myelodysplasia: susceptibility and incidence.
Leone G; Pagano L; Ben-Yehuda D; Voso MT
Haematologica; 2007 Oct; 92(10):1389-98. PubMed ID: 17768113
[TBL] [Abstract][Full Text] [Related]
4. Therapy-related myelodysplasia and acute myeloid leukemia.
Bhatia S
Semin Oncol; 2013 Dec; 40(6):666-75. PubMed ID: 24331189
[TBL] [Abstract][Full Text] [Related]
5. Role of MTHFR (677, 1298) haplotype in the risk of developing secondary leukemia after treatment of breast cancer and hematological malignancies.
Guillem VM; Collado M; Terol MJ; Calasanz MJ; Esteve J; Gonzalez M; Sanzo C; Nomdedeu J; Bolufer P; Lluch A; Tormo M
Leukemia; 2007 Jul; 21(7):1413-22. PubMed ID: 17476281
[TBL] [Abstract][Full Text] [Related]
6. Incidence of secondary myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) in patients with ovarian or breast cancer in a real-world setting in the United States.
Shenolikar R; Durden E; Meyer N; Lenhart G; Moore K
Gynecol Oncol; 2018 Nov; 151(2):190-195. PubMed ID: 30268525
[TBL] [Abstract][Full Text] [Related]
7. The incidence of secondary leukemias.
Leone G; Mele L; Pulsoni A; Equitani F; Pagano L
Haematologica; 1999 Oct; 84(10):937-45. PubMed ID: 10509043
[TBL] [Abstract][Full Text] [Related]
8. Pooled analysis of clinical and cytogenetic features in treatment-related and de novo adult acute myeloid leukemia and myelodysplastic syndromes based on a consecutive series of 761 patients analyzed 1976-1993 and on 5098 unselected cases reported in the literature 1974-2001.
Mauritzson N; Albin M; Rylander L; Billström R; Ahlgren T; Mikoczy Z; Björk J; Strömberg U; Nilsson PG; Mitelman F; Hagmar L; Johansson B
Leukemia; 2002 Dec; 16(12):2366-78. PubMed ID: 12454741
[TBL] [Abstract][Full Text] [Related]
9. Therapy-related myelodysplasia and acute myeloid leukemia. Cytogenetic characteristics of 115 consecutive cases and risk in seven cohorts of patients treated intensively for malignant diseases in the Copenhagen series.
Pedersen-Bjergaard J; Philip P; Larsen SO; Andersson M; Daugaard G; Ersbøll J; Hansen SW; Hou-Jensen K; Nielsen D; Sigsgaard TC
Leukemia; 1993 Dec; 7(12):1975-86. PubMed ID: 8255096
[TBL] [Abstract][Full Text] [Related]
10. Incidence and susceptibility to therapy-related myeloid neoplasms.
Leone G; Fianchi L; Pagano L; Voso MT
Chem Biol Interact; 2010 Mar; 184(1-2):39-45. PubMed ID: 20026017
[TBL] [Abstract][Full Text] [Related]
11. Inversion of chromosome 16 and uncommon rearrangements of the CBFB and MYH11 genes in therapy-related acute myeloid leukemia: rare events related to DNA-topoisomerase II inhibitors?
Dissing M; Le Beau MM; Pedersen-Bjergaard J
J Clin Oncol; 1998 May; 16(5):1890-6. PubMed ID: 9586906
[TBL] [Abstract][Full Text] [Related]
12. Therapy-related acute myeloid leukemia secondary to inhibitors of topoisomerase II: from the bedside to the target genes.
Ratain MJ; Rowley JD
Ann Oncol; 1992 Feb; 3(2):107-11. PubMed ID: 1318741
[TBL] [Abstract][Full Text] [Related]
13. Genetics of therapy-related myelodysplasia and acute myeloid leukemia.
Pedersen-Bjergaard J; Andersen MK; Andersen MT; Christiansen DH
Leukemia; 2008 Feb; 22(2):240-8. PubMed ID: 18200041
[TBL] [Abstract][Full Text] [Related]
14. Genetic variants involved in oxidative stress, base excision repair, DNA methylation, and folate metabolism pathways influence myeloid neoplasias susceptibility and prognosis.
Gonçalves AC; Alves R; Baldeiras I; Cortesão E; Carda JP; Branco CC; Oliveiros B; Loureiro L; Pereira A; Nascimento Costa JM; Sarmento-Ribeiro AB; Mota-Vieira L
Mol Carcinog; 2017 Jan; 56(1):130-148. PubMed ID: 26950655
[TBL] [Abstract][Full Text] [Related]
15. Profile of polymorphisms of drug-metabolising enzymes and the risk of therapy-related leukaemia.
Bolufer P; Collado M; Barragan E; Calasanz MJ; Colomer D; Tormo M; González M; Brunet S; Batlle M; Cervera J; Sanz MA
Br J Haematol; 2007 Feb; 136(4):590-6. PubMed ID: 17367411
[TBL] [Abstract][Full Text] [Related]
16. Mutations with loss of heterozygosity of p53 are common in therapy-related myelodysplasia and acute myeloid leukemia after exposure to alkylating agents and significantly associated with deletion or loss of 5q, a complex karyotype, and a poor prognosis.
Christiansen DH; Andersen MK; Pedersen-Bjergaard J
J Clin Oncol; 2001 Mar; 19(5):1405-13. PubMed ID: 11230485
[TBL] [Abstract][Full Text] [Related]
17. Therapy-related acute myeloid leukemia and myelodysplasia after successful treatment of acute promyelocytic leukemia.
Zompi S; Viguié F
Leuk Lymphoma; 2002 Feb; 43(2):275-80. PubMed ID: 11999558
[TBL] [Abstract][Full Text] [Related]
18. The secondary leukemias: challenges and research directions.
Smith MA; McCaffrey RP; Karp JE
J Natl Cancer Inst; 1996 Apr; 88(7):407-18. PubMed ID: 8618232
[TBL] [Abstract][Full Text] [Related]
19. Promoter methylation of DAPK1, E-cadherin and thrombospondin-1 in de novo and therapy-related myeloid neoplasms.
Greco M; D'Alò F; Scardocci A; Criscuolo M; Fabiani E; Guidi F; Di Ruscio A; Migliara G; Pagano L; Fianchi L; Chiusolo P; Hohaus S; Leone G; Voso MT
Blood Cells Mol Dis; 2010 Oct; 45(3):181-5. PubMed ID: 20655775
[TBL] [Abstract][Full Text] [Related]
20. Chromosomal abnormalities in secondary MDS and AML. Relationship to drugs and radiation with specific emphasis on the balanced rearrangements.
Andersen MK; Johansson B; Larsen SO; Pedersen-Bjergaard J
Haematologica; 1998 Jun; 83(6):483-8. PubMed ID: 9676019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
